2026
GPPAD Publications
- Determinants of Infant Participation and Non-Participation in Primary Prevention Trials.
Wörl F, Achenbach P, et al. (2026). Hormone and Metabolic Research. In press
History
The Global Platform for the Prevention of Autoimmune Diabetes
2026
July 2026
New GPPAD Site Milan, Italy
New GPPAD Site Milan Started Screening & Enrollment into AVAnT1A
(PI: Emanuele Bosi)
May 2026
18th GPPAD Investigator Meeting in Starnberg / Munich, Germany
2025
2025
GPPAD Publications
- Efficacy of once-daily high-dose oral insulin immunotherapy in children genetically at risk for type 1 diabetes: A European randomized, placebo-controlled primary prevention trial (POInT).
Ziegler AG, Achenbach P, Weiss A, et al. (2025). The Lancet, 406, 2564-2576. - Epigenetic differences at immune and type 1 diabetes susceptibility genes in blood from young children after COVID-19 infection.
Ott R, Singh T, et al. (2025). Journal of Autoimmunity. - Genetics of circulating proteins in newborn babies at high risk of type 1 diabetes.
Tutino M, Yu NY, et al. (2025). Nature Communications, 16(1), 3750. - Blood methylome signatures in children exposed to maternal type 1 diabetes are linked to protection against islet autoimmunity.
Ott R, Zapardiel-Gonzalo J, et al. (2025). Nature Metabolism. - Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocol.
Hummel S, Käßl A, et al. (2025). Contemporary Clinical Trials Communications.
November 2025
17th GPPAD Online Investigator Meeting
April 2025
16th GPPAD Investigator Meeting in London, UK
Our annual GPPAD Investigator meeting took place in London, where we shared valuable insights and important updates from our research – and also marked a special milestone: 10 years of GPPAD research.
2024
2024
GPPAD Publications
- Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemic.
Zeller I, Ziegler AG, et al. (2024). Infection, 52(6), 2465–2473. - Early-childhood body mass index and its association with the COVID-19 pandemic, containment measures and islet autoimmunity in children with increased risk for type 1 diabetes.
Hummel S, Ziegler AG, et al. (2024). Diabetologia, 67(4), 670–678. - Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes.
Hendriks E, Marcovecchio L, et al. (2024). Diabetes/Metabolism Research and Reviews, 40(2), e3777. - Vitamin D insufficiency in infants with increased risk of developing type 1 diabetes: A secondary analysis of the POInT study.
Jacobs A, Warnants M, et al. (2024). BMJ Paediatrics Open, 8(1), e002212.
November 2024
New GPPAD Site Cambridge, UK
New GPPAD Site Cambridge Started Screening & Enrollment into AVAnT1A
(PIs: Loredana Marcovecchio & Katarzyna Gajewska-Knapik)
November 2024
Diabetes Awareness Month Activity Challenge
November 14 is World Diabetes Day – and to mark the occasion, we launched a special team challenge to raise awareness for Type 1 Diabetes. Using the Strava app, our whole Europe team collected activity minutes – and together we reached an amazing 35,000+ minutes of activity!
A huge thank you to everyone who contributed their time and energy. Every minute counts in raising awareness and showing support for those living with Type 1 Diabetes.
November 2024
15th GPPAD Online Investigator Meeting
June 2024
Last Patient Last Visit POInT in Munich, Hanover and Dresden, Germany (1,050 in Total)
May/June 2024
1st Children Enrolled in AVAnT1A in Hanover & Dresden, Germany & Malmö, Sweden
April 2024
14th GPPAD Investigator Meeting in Malmö, Sweden
April 2024
Ethic Committee Approval for the AVAnT1A Study (Antiviral Action against Type 1 diabetes Autoimmunity)
To Prevent Type 1 Diabetes Through a Sars-Cov-2 Vaccination and Investigate the Link Between Type 1 Diabetes and Viral Infections.
2,252 Participants (Planned)
- Improved Newborn Screening: GRS 47 SNPs, Sex-Specific
- GPPAD Ancillary Site: Collaboration with Heikki Hyöty & Sami Oikarinen (University of Tampere, Finland) on Measuring Viral Antibodies in AVAnT1A
February 2024
GPPAD Celebrates 1,049 Participants in SINT1A Study.
Last Child Enrolled in Newcastle, UK
2023
2023
GPPAD Publications
- SARS-CoV-2 infection and development of islet autoimmunity in early childhood.
Bonifacio E, Lugar M, et al. (2023). JAMA, 330(12), 1151–1160. - Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.
Bendor-Samuel OM, Wishlade T, Willis L, et al.; GPPAD Study Group. (2023). Archives of Disease in Childhood, 108(1), 26–30.
December 2023
1st Child Completed the Intervention Phase in POInT in Dresden, Germany
November 2023
500,000 Babies Screened
November 2023
World Diabetes Day
K1DS ARE HEROES – Meet our Superheroes from all across Europe.
November 2023
Launch of the pre-T1D Registry Europe-Wide Registration of Individuals with Early Stages of Type 1 Diabetes, Organized at Helmholtz Munich and Including Data from GPPAD
October 2023
13th GPPAD Online Investigator Meeting
April 2023
12th GPPAD Investigator Meeting in Leuven, Belgium
March 2023
Cyber Attack at Helmholtz Munich, Home of the GPPAD Coordinating Center
Team Effort to Keep Administrative Work and Communication Going, While Maintaining Key Operations Like Recruitment and Project Activities Despite the Disruption.
February 2023
K1DS ARE HEROES Campaign
Awareness Campaign on Early Detection and Prevention of Type 1 Diabetes
2022
2022
GPPAD Publications
- The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT study.
Houben J, Janssens M, et al. (2022). Pediatric Diabetes, 23(8), 1707–1716. - Elevations in blood glucose before and after the appearance of islet autoantibodies in children.
Warncke K, Weiss A, et al. (2022). Journal of Clinical Investigation, 132(20), e162123.
December 2022
Start Ancillary POInT Research (RFP)
GPPAD Announced a Request for Proposal (RFP) for Innovative Research on Biosamples From the
GPPAD POInT Clinical Trial Utilizing Cutting-Edge Analysis Techniques Relevant to Pancreatic, Metabolic, or Immune Research. 5 od 18 Submission were Selected For Funding
November 2022
World Diabetes Day Passing the Blue Heart
October 2022
11th GPPAD Online Investigator Meeting
July 2022
New GPPAD Site Newcastle Started Screening & Enrollment into SINT1A
(PIs: Catherine Owen & Stephen Robson)
May 2022
10th GPPAD Investigator Meeting in Munich, Germany
2021
2021
GPPAD Publication
- Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: The GPPAD-SINT1A randomized controlled trial protocol.
Ziegler AG, Arnolds S, et al. (2021). BMJ Open, 11(11), e052449
October 2021
9th GPPAD Online Investigator Meeting
June 2021
In Remembrance of Jörg Hasford – a Member of the GPPAD Team & Steering Committee
June 2021
8th GPPAD Online Investigator Meeting
April 2021
1st Children Enrolled in SINT1A in Hanover, Germany
March 2021
GPPAD Celebrates 1,050 Participants in POInT.
Last Child Enrolled in Oxford, UK
January 2021
Ethic Committee Approval for the SINT1A Study (Supplementation with B. INfantis for Mitigation of Type 1 Diabetes Autoimmunity)
Prevention of Type 1 Diabetes Through the Development of a Healthy Gut Microbiome with Probiotics
1,149 Participants (Recruitment Concluded in 2023)
- Improved Newborn Screening: 51 SNPs (including BTNL2)
- Initiate Fast Turnaround for SINT1A Enrollment of Newborns at 6
Weeks → Weekly Shipments to LGC
January 2021
GPPAD Science Newsletter: 5 Editions So Far and Over 200 Subscribers
2020
November 2020
7th GPPAD Online Investigator Meeting
July 2020
1st POInT Children Start Follow-Up Phase in Dresden & Munich, Germany
→ Start Retention Strategy With Our Study Mascot UNO
March 2020
6th GPPAD Investigator Meeting and 1st Online Meeting
February 2020
COVID-19 Pandemic: Collaborative Effort to Continue Study Enrollments
and Keep the Central Lab in Munich, Germany Running
2019
2019
GPPAD Publications
- Identification of infants with increased type 1 diabetes genetic risk for enrollment into primary prevention trials – GPPAD-02 study design and first results.
Winkler C, Haupt F, et al.; GPPAD Study Group. (2019). Pediatric Diabetes, 20(6), 720–727. - Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: The GPPAD-POInT study protocol.
Ziegler AG, Achenbach P, et al. (2019). BMJ Open, 9(6), e028578.
October 2019
5th GPPAD Investigator Meeting in Warsaw, Poland
July 2019
100,000 Babies Screened
May 2019
4th GPPAD Investigator Meeting in Munich, Germany
May 2019
Welcome to UNO
Introducing Our Study Mascot – A Key Element of the GPPAD Communication Strategy, Created by Identitätsstiftung
2018
December 2018
3rd GPPAD Investigator Meeting in Dresden, Germany & Round Table Discussion: “Should Screening for Type 1 Diabetes Become Part of Standard Healthcare?”
August 2018
Oxford Started Screening and POInT
→ Principle Investigator (PI): Rachel Besser, former PI: Matthew Snape
June 2018
2nd GPPAD Investigator Meeting in Oxford, UK
February 2018
1st Child Enrolled in POInT in Dresden, Germany
→ Improved Newborn Screening: 47 SNPs
2017
November 2017
1st GPPAD Investigator Meeting, in Munich, Germany
November 2017
Ethic Committee Approval for the Primary Oral Insulin Trial (POInT)
Prevention of Type 1 Diabetes by Training the Immune System Using Oral Insulin.
1,050 Participants (Recruitment Concluded in 2021)
July 2017
Ethic Committee Approval for GPPAD-02 – Genetic Screening for Newborns from the General Population & 1st Baby Screened
→ Introducing a New Genetic Risk Score Identifying Infants With a >10% Risk of Developing
Multiple Beta-Cell Autoantibodies
April 2017
Official Launch of the GPPAD Platform – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD)
- Establishment of the GPPAD Coordinating Center at the Institute of Diabetes Research, Helmholtz Munich
- Formation of the GPPAD Steering Committee
Founding Steering Committee Members: Gina Agiostratidou, Ezio Bonifacio, Kristina Casteels, Jörg Hasford, Helena Elding Larsson, Olga Kordonouri, Matthew Snape, Agnieszka Szypowska, Anette-Gabriele Ziegler - Creation of the Data Safety and Monitoring Board (DSMB) to Facilitate Regular DSMB Reports for All GPPAD Clinical Trials
Members: Polly Bingley, Ulrich Heininger, Markus Pfirrmann, Wolfgang Rascher, Paul Turner - GPPAD Screening Database Finalized
Person Primarily Responsible: Florian Haupt
March 2017
GPPAD Kick-off Meeting in Malmö, Sweden
2016
September 2016
GPPAD 01 – The Freder1k Pilot Study in Saxony, Germany
The Freder1k Pilot Study Was a Model Project to Test Newborns in the Context of
the Established Newborn Screening for High Risk to Develop Type 1 Diabetes
First 5,000 Babies Screened
→ Start of High Throughput Genetic Screening for HLA Genes with LGC
July 2016
U.S. visit with Helmsley Charitable Trust to Eli Lilly’s Indianapolis IAPI Facility—
Securing 50 kg Insulin Crystals for the POInT – Primary Oral Insulin Trial
February 2016
Accepted Manuscript
- Primary prevention of beta-cell autoimmunity and type 1 diabetes – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives.
Ziegler AG, Danne T, Dunger DB, et al. (2016). Molecular Metabolism, 5(4), 255–262.
2015
How It Started – January:
The Helmsley Charitable Trust (HCT) Prevention Alliance for Type 1 Diabetes (HPAT) European Platform was granted to Cambridge and Munich, Germany.
Survey on Willingness of Pregnant Women to Participate in Primary Prevention Trials
2/3 of Pregnant Women Are Likely to Participate in a Trial
2014
Early Steps
Meetings
With Anette-Gabriele Ziegler, Ezio Bonifacio, John Todd and the Helmsley Charitable Trust (David Panzirer, Gina Agiostratidou) to Draft an Action Plan for The Helmsley Charitable Trust (HCT) Prevention Alliance for Type 1 Diabetes (HPAT) European Platform